SCHEMBL533193

SCHEMBL533193

O=C(O)C1Cc2c(ccc3[nH]ccc23)N1

nearest known ligand 0.44

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.44
GAA P10253 1/20 0.44
KDM4E B2RXH2 2/20 0.39
ALDH1A1 P00352 2/20 0.39
HPGD P15428 2/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
CYP2D6 P10635 1/20 0.38
TSHR P16473 1/20 0.38
MAPK1 P28482 1/20 0.38
TP53 P04637 1/20 0.37
CYP1A2 P05177 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
HSD17B10 Q99714 1/20 0.37
HTR1D P28221 5/20 0.37
HTR1B P28222 3/20 0.37
MAPK14 Q16539 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5384437 0.85 MAPT (0.33) MAPTGAAKDM4EALDH1A1HPGD
SCHEMBL532722 0.85 MAPT (0.33) MAPTGAAKDM4EALDH1A1HPGD
SCHEMBL533321 0.83 KDM4E (0.45) MAPTGAAKDM4EALDH1A1HPGD
SCHEMBL7132853 0.74 MAPT (0.53) MAPTGAAKDM4EALDH1A1HPGD
SCHEMBL3419671 0.72 GAA (0.41) MAPTGAAKDM4EALDH1A1HPGD
SCHEMBL5388942 0.71 KDM4E (0.36) MAPTGAAKDM4EALDH1A1HPGD
SCHEMBL9408601 0.69 MAPT (0.46) MAPTGAAKDM4EALDH1A1HPGD
SCHEMBL5568616 0.69 MAPT (0.43) MAPTGAAKDM4EALDH1A1HPGD
SCHEMBL6876168 0.69 MAPK1 (0.38) KDM4EALDH1A1MEN1KMT2AMAPK1
SCHEMBL12620402 0.68 GAA (0.45) MAPTGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1430147-B1 FLUORESCENT QUENCHING DETECTION REAGENTS AND METHODS EPOCH BIOSCIENCES INC (US) 2013-05-22 EP disclosed
EP-1235938-B1 FLUORESCENT QUENCHING DETECTION REAGENTS AND METHODS EPOCH BIOSCIENCES INC (US) 2012-02-08 EP disclosed
US-7897736-B2 Fluorescent quenching detecting reagents and methods ELITECH HOLDING B.V. (NL) 2011-03-01 US disclosed
US-20100174058-A1 FLUORESCENT QUENCHING DETECTING REAGENTS AND METHODS ELITECHGROUP, INC. 2010-07-08 US disclosed
US-7662942-B2 Oligonucleotide probes containing two labels useful in hybridization assays Elitech Holdings, B.V. (NL) 2010-02-16 US disclosed
EP-1430147-A4 FLUORESCENT QUENCHING DETECTION REAGENTS AND METHODS EPOCH BIOSCIENCES INC (US) 2008-06-25 EP disclosed
US-20060292589-A1 Oligonucleotide probes containing two labels useful in hybridization assays EPOCH BIOSCIENCES, INC. (US) 2006-12-28 US disclosed
US-20040191796-A1 Fluorescent quenching detection reagents and methods EPOCH PHARMACEUTICALS, INC. (US) 2004-09-30 US disclosed
US-6790945-B2 OLIGONUCLEOTIDE PROBES CONTAINING TWO LABELS USEFUL IN HYBRIDIZATION ASSAYS EPOCH BIOSCIENCES, INC. 2004-09-14 US disclosed
EP-1430147-A1 FLUORESCENT QUENCHING DETECTION REAGENTS AND METHODS Epoch Biosciences, Inc. (US) 2004-06-23 EP disclosed
US-6727356-B1 AS PROBES SUCH AS FOR FLUORESCENCE RESONANCE ENERGY TRANSFER; QUENCHER INCLUDES A 4-(PHENYLDIAZENYL)PHENYLAMINE STRUCTURE; IMPROVED SIGNAL TO NOISE RATIO AND HYBRIDIZATION EPOCH PHARMACEUTICALS, INC. 2004-04-27 US disclosed
US-6699975-B2 OLIGONUCLEOTIDE FOR USE AS TOOL IN THE DETECTION OF PREFERENTIAL COMPOUNDS IN SOLUTION EPOCH BIOSCIENCES, INC. 2004-03-02 US disclosed
US-6653473-B2 Nucleotide sequences for use as diagnostic tool in genetic analysis EPOCH BIOSCIENCES, INC. 2003-11-25 US disclosed
US-20030096254-A1 Enhancing resonance ability of oligonuclotide probes for use in hybridization assays; gene expression EPOCH BIOSCIENCES, INC. (US) 2003-05-22 US disclosed
US-20030008304-A1 Fluorescent quenching detection reagents and methods EPOCH BIOSCIENCES, INC. (US) 2003-01-09 US disclosed
WO-2002099141-A1 FLUORESCENT QUENCHING DETECTION REAGENTS AND METHODS EPOCH BIOSCIENCES, INC. (US) 2002-12-12 WO disclosed
US-20020155484-A1 Fluorescent quenching detection reagents and methods EPOCH PHARMACEUTICALS, INC. (US) 2002-10-24 US disclosed
EP-1235938-A2 FLUORESCENT QUENCHING DETECTION REAGENTS AND METHODS Epoch Biosciences, Inc. (US) 2002-09-04 EP disclosed
US-20020034754-A1 Fluorescent quenching detection reagents and methods ELITECHGROUP, INC. 2002-03-21 US disclosed
WO-2001042505-A2 FLUORESCENT QUENCHING DETECTION REAGENTS AND METHODS EPOCH BIOSCIENCES, INC. (US) 2001-06-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030008304-A1 Fluorescent quenching detection reagents and methods DDX5, DDX21, DCLRE1B MAPT 4772/4885GAA 1168/4885KDM4E 4634/4885
US-20020034754-A1 Fluorescent quenching detection reagents and methods DDX5, DDX21, DCLRE1B MAPT 4772/4885GAA 1168/4885KDM4E 4634/4885
US-20100174058-A1 FLUORESCENT QUENCHING DETECTING REAGENTS AND METHODS DDX5, DDX21, DCLRE1B MAPT 4706/4885GAA 1153/4885KDM4E 4651/4885
US-20060292589-A1 Oligonucleotide probes containing two labels useful in hybridization assays DCLRE1B, DDX21, DCLRE1A MAPT 4727/4885GAA 1978/4885KDM4E 4819/4885
US-20020155484-A1 Fluorescent quenching detection reagents and methods IPO4, PTBP3, DDX5 MAPT 4738/4885GAA 3253/4885KDM4E 3864/4885
US-20040191796-A1 Fluorescent quenching detection reagents and methods DDX5, IPO4, DBF4 MAPT 4825/4885GAA 3182/4885KDM4E 3259/4885
US-20030096254-A1 Enhancing resonance ability of oligonuclotide probes for use in hybridization assays; gene expression DCLRE1B, SNRPE, ZFR MAPT 4863/4885GAA 2186/4885KDM4E 4757/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.